Notice of Allowance Covers Compounds, Compositions, and Methods for Treating HK2-Expressing Cancers
London (UK), September 30th , 2025 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a novel class of cancer treatments, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent entitled “Use of Hexokinase 2/Mitochondria-Detaching Compounds for Treating Hexokinase-2 (HK2)-Expressing Cancers.”
The claims provide broad protection for Vidac’s proprietary technology, covering a wide range of HK2/VDAC1 detaching compounds in mitochondria, pharmaceutical compositions containing such compounds, and methods of treating, inhibiting, or suppressing any cancer that expresses HK2, a key driver of tumor metabolism and survival.
This allowance significantly broadens Vidac’s intellectual property rights, ensuring coverage across multiple compound classes, formulations, and cancer indications. It represents a major step in consolidating the Company’s leadership in the development of cancer metabolism therapeutics.
Dr. Max Herzberg, CEO of Vidac Pharma, commented:
“This patent allowance represents a major milestone for Vidac, significantly strengthening our IP portfolio in oncology. The broad scope of protection reflects the novelty and potential of our Mitochondrial targeting approach, and positions Vidac at the forefront of cancer metabolism therapeutics. The role of "healthy" mitochondria in fighting cancer is now a hot subject: Vidac is curing the block of programmed death occurring in cancer cells by reversing the Warburg effect and making the Tumor Microenvironment (TME) pro-immune again.”
For more information please contact:
Vidac Pharma Holding Plc
Dr Max Herzberg
20-22 Wenlock Road
London N1 7GU
United Kingdom
http://www.vidacpharma.com/
investors@vidacpharma.com
+972-54-4257381
About Vidac Pharma
Vidac Pharma is a clinical-stage biopharmaceutical company dedicated to discovering and developing first-in-class medicines to help people suffering from a range of oncologic and onco-dermatologic diseases. Vidac develops first-in-class anti-cancer drugs by modifying the hyper-glycolytic tumor microenvironment, targeting the overexpression and wrong anchoring of the Hexokinase 2 metabolic checkpoint (HK2) in cancer cells, to renormalize tumor microenvironment and selectively provoke their programmed death, without affecting surrounding normal tissue. VDA-1102, a first drug candidate of Vidac Pharma has shown to be effective against advanced Actinic Keratosis (AK), while interim results in Cutaneous T-cell Lymphoma (CTCL) yielded a positive effect in Phase 2 trials in humans.
Important information
The information in this press release does not constitute a public offer to sell or a solicitation to submit an offer to buy or subscribe to shares of Vidac Pharma Holding PLC, but is for informational purposes only. The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.